PZ Wind Down IncOver The Counter Market:PZRXQ
- LAST PRICE0.0002
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0002
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
PZ Wind Down Inc | 2.3K | 0.0x | --- |
Oncovista Innovative Therapies Inc | 2.4K | 0.0x | --- |
Omnimmune Holdings Inc | 940.0 | 0.0x | --- |
VIA Pharmaceuticals Inc | 20.0 | 0.0x | --- |
Anthera Pharmaceuticals Inc | 30.0 | 0.0x | --- |
Cantabio Pharmaceuticals Inc | 22.8K | 0.0x | --- |
Company Information
Pz Wind Down, Inc., formerly, PhaseRx, Inc. is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.
Contact Information
- Headquarters
- 410 W Harrison St Ste 300SEATTLE, WA, United States 98119-4034
- Phone
- 206-805-6300
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Steven Gillis
- President, Chief Executive Officer, Principal Accounting Officer, Secretary, Director
- Robert Overell
- Vice President - Chemistry
- Sean Monahan
- Vice President - Biology
- Mary Prieve
- Chief Medical Officer
- Gordon Brandt
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.3K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 11.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.12 |
EPS | $-1.19 |
Book Value | $0.80 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
